Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

Edeline, Julien; Blanc, Jean‐Frédéric; Campillo‐Gimenez, Boris; Ma, Y.T.; King, James P.; Faluyi, Olusola Olusesan; Mathurin, J.; Ghazi, Samer; Palmer, Daniel H.; Meyer, Tim

doi:10.1016/j.ejca.2017.08.036

Cited by 21 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, several clinical and laboratory factors, such as tumor etiology, Child–Pugh score, alpha-fetoprotein (AFP), platelets and gamma-glutamyl transferase have been proposed as predictors of tumor progression and survival in patients on Sorafenib [ 12 ]. In addition, several prognostic scores have been specifically set up in order to evaluate the prognosis of these patients, such as the PROSASH model, its “optimized” version PROSASH-II [ 12 , 13 ] and the SAP score [ 14 ]. Besides, even “not dedicated” prognostic scores already used for HCC staging, such as the Barcelona Clinic Liver Cancer (BCLC), the Okuda score and the Cancer of the Liver Italian Program (CLIP) score [ 15 , 16 ], have been tested with the same purpose.…”

Section: Introductionmentioning

confidence: 99%

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

Marasco

Poggioli

Colecchia

et al. 2021

Cancers

View full text Add to dashboard Cite

Among scores and staging systems used for HCC, none showed a good prognostic ability in patients with advanced HCC treated with Sorafenib. We aimed to evaluate predictive factors of overall survival (OS) and drug response in HCC patients undergoing Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Patients in the ITA.LI.CA database treated with Sorafenib and updated on 30 June 2019 were included. Demographic and clinical data before starting Sorafenib treatment were considered. For the evaluation of predictive factors for OS, a time-dependent Cox proportional hazard model was used. A total of 1107 patients were included in our analysis. The mean age was 64.3 years and 81.7% were male. Most patients were staged as BCLC B (205, 18.9%) or C (706, 65.1%). The median time of Sorafenib administration was 4 months (interquartile range (IQR) 2–12), and the median OS was 10 months (IQR: 4–20). A total of 263 patients (33.8%) out of 780 with available evaluation experienced objective tumoral response to Sorafenib. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (hazard ratio (HR) 1.284), maximum tumoral diameter (HR 1.100), plasma total bilirubin (HR 1.119), aspartate amino transferase assessed as multiple of the upper normal value (HR 1.032), alpha-fetoprotein ≥200 ng/mL (HR 1.342), hemoglobin (HR 0.903) and platelet count (HR 1.002) were associated with OS at multivariate Cox regression analysis. Drug response was predicted by maximum tumoral diameter and platelet count. A novel prognostic nomogram for patients undergoing Sorafenib is hereby proposed. The novelty introduced is the comprehensive patient’s assessment using common markers of patient’s general status, liver damage and function and HCC biology. Further studies are required to test its accuracy and provide external validation.

show abstract

Section: Introductionmentioning

confidence: 99%

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

Marasco

Poggioli

Colecchia

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In this context, previous studies have indicated that tumor stage, tumor size, and multiple tumors were strong predictors of poor OS in PHCC cases [ 27 – 29 ]. The present study was also emphasized the importance of tumor burden consistent with those findings and identified the optimal cut-off value as 3.0 cm of tumor size based on the X-tile analysis, as well as optimal cut-off values for PT and AST, which are known markers of liver failure based on previous studies [ 30 , 31 ].…”

Section: Discussionmentioning

confidence: 96%

Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma

Zhou

Cai

Hou

et al. 2020

Aging

View full text Add to dashboard Cite

Background: Primary hepatocellular carcinoma (PHCC) has a poor prognosis and high short-term mortality rate, even after resection. Thus, early diagnosis in PHCC cases can help improve quality of life via personalized management strategies. Results: The risk score system (RSS) were classified as low risk (<5 points), medium risk (5–10 points), or high risk (>10 points). The areas under the receiver operating characteristic curves were 0.80 in the training cohort and 0.69 in the validation cohort, which indicated satisfactory prognostic performance. The Hosmer-Lemeshow goodness of fit test ( P >0.05) revealed consistent performance in both groups. The concordance index (C-index: 0.663, 95% CI: 0.618–0.708) revealed excellent discrimination and good calibration in the validation cohort. Conclusions: This simple RSS, which is based on clinical and laboratory data from patients undergoing resection of PHCC, might allow clinicians and medical staff to better manage PHCC. Materials and Methods: A total of 672 PHCC cases were retrospectively obtained from the First Affiliated Hospital of Wenzhou Medical University between January 2007 and February 2015. Cox proportional hazard models were used to identify independent predictors of mortality. Kaplan-Meier curves and the log-rank test were used to examine the relationships between the prognostic factors and overall mortality.

show abstract

“…Our study describes a simple, cost-effective scoring system associated with improved survival in patients with HCC treated with sorafenib. While many new scoring systems are available for this purpose, they tend to include variables that are too financially prohibitive or too administratively cumbersome for under-staffed, resource-limited settings ( 3 , 5 , 6 ). Many physicians rely on BCLC staging to determine sorafenib eligibility, but as this clinical tool is dependent on advanced imaging modalities, its utility is severely limited.…”

Section: Discussionmentioning

confidence: 99%

PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings

Leathers¹,

Balderramo²,

Prieto³

et al. 2018

Hepat Mon

View full text Add to dashboard Cite

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

Abstract: In European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making.

Cited by 21 publications

References 23 publications

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma

PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings

Contact Info

Product

Resources

About